799P - Prognostic value of computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Prostate Cancer
Staging Procedures (clinical staging)
Basic Principles in the Management and Treatment (of cancer)
Imaging
Presenter Shuko Yoneyama
Citation Annals of Oncology (2014) 25 (suppl_4): iv255-iv279. 10.1093/annonc/mdu336
Authors S. Yoneyama1, Y. Miyoshi1, S. Takebayashi2, K. Noguchi1
  • 1Urology, Yokohama City University Medical Center, 2320024 - Yokohama/JP
  • 2Radiology, Yokohama City University Medical Center, 2320024 - Yokohama/JP

Abstract

Aim

Computer-aided bone scan index (CA-BSI) has recently been expected to be an objective and quantitative clinical tool for evaluation of the bone metastasis of prostate cancer. The objective of this study was to evaluate the CA-BSI for prognostic factor in hormone-naive prostate cancer with bone metastases.

Methods

The study included 75 hormone-naive prostate cancer patients with bone metastases initially treated with combined androgen blockade therapy between 2005 and 2013 at our institution. BONENAVI® system was used for calculation program of CA-BSI. We evaluated the correlation between prognosis and clinicopathological characteristics, value of PSA, extent of disease (EOD) grade, pretreatment bone scan index (BSI) and the number of hot spots. Statistical analyses were assessed using cox proportional hazards regression models.

Results

The mean age was 73 years old and median follow-up duration was 28.5 months. Zoledronic acid was used for 30 patients (40%) and 21 patients (28%) were received chemotherapy with docetaxel for castration-resistant. Multivariate analysis revealed that BSI (p = 0.002) and the number of hot spots (p < 0.01) were associated with cancer specific survival.

Conclusions

BSI and the number of hot spots were effective prognostic factors for hormone-naive prostate cancer with bone metastases. An objective and quantitative method such as CA-BSI with BONENAVI® system should be performed for evaluating bone metastases in prostate cancer patients.

Disclosure

All authors have declared no conflicts of interest.